Key result
Transcatheter aortic valve replacement was associated with lower 30-day mortality (3.1% vs 7.8%) but similar 4-year survival (65.9% vs 69.6%) compared to surgical replacement in patients with severe aortic stenosis and reduced ejection fraction.
Why the study?
Patients with severe aortic stenosis and left ventricular systolic dysfunction have a poor prognosis that may result in inferior survival after aortic valve replacement, prompting a comparison of transcatheter and surgical approaches.
Does transcatheter aortic valve replacement improve survival compared to surgical aortic valve replacement in patients with severe aortic stenosis and left ventricular dysfunction?
Cohort (n=6,463)
Yes
Does transcatheter aortic valve replacement improve survival compared to surgical aortic valve replacement in patients with severe aortic stenosis and left ventricular dysfunction?
Effect estimate: RMST ratio 1.002 (95% CI 0.929-1.080)
Absolute Event Rate: 65.9% vs 69.6%
p-value: p=0.964
In patients with severe aortic stenosis and reduced LVEF, TAVR is associated with lower 30-day mortality compared to SAVR, but both strategies offer comparable intermediate-term survival.
Reduced LVEF raises post-AVR mortality; matched data show higher 30-day SAVR risk but similar intermediate survival, leaving optimal choice open.
BACKGROUND: Patients with severe aortic stenosis and left ventricular systolic dysfunction have a poor prognosis, and this may result in inferior survival also after aortic valve replacement. The outcomes of transcatheter and surgical aortic valve replacement were investigated in this comparative analysis. METHODS: The retrospective nationwide FinnValve registry included data on patients who underwent transcatheter or surgical aortic valve replacement with a bioprosthesis for severe aortic stenosis. Propensity score matching was performed to adjust the outcomes for baseline covariates of patients with reduced (≤ 50%) left ventricular ejection fraction. RESULTS: Within the unselected, consecutive 6463 patients included in the registry, the prevalence of reduced ejection fraction was 20.8% (876 patients) in the surgical cohort and 27.7% (452 patients) in the transcatheter cohort. Reduced left ventricular ejection fraction was associated with decreased survival (adjusted hazards ratio 1.215, 95%CI 1.067-1.385) after a mean follow-up of 3.6 years. Among 255 propensity score matched pairs, 30-day mortality was 3.1% after transcatheter and 7.8% after surgical intervention (p = 0.038). One-year and 4-year survival were 87.5% and 65.9% after transcatheter intervention and 83.9% and 69.6% after surgical intervention (restricted mean survival time ratio, 1.002, 95%CI 0.929-1.080, p = 0.964), respectively. CONCLUSIONS: Reduced left ventricular ejection fraction was associated with increased morbidity and mortality after surgical and transcatheter aortic valve replacement. Thirty-day mortality was higher after surgery, but intermediate-term survival was comparable to transcatheter intervention. Trial registration The FinnValve registry ClinicalTrials.gov Identifier: NCT03385915.
No takes yet. Share an insight, caveat, or question.
Jalava et al. (2022) conducted a cohort in Severe aortic stenosis with left ventricular dysfunction (n=6,463). Transcatheter aortic valve replacement (TAVR) vs. Surgical aortic valve replacement (SAVR) was evaluated on 4-year survival (RMST ratio 1.002, 95% CI 0.929-1.080, p=0.964). Transcatheter aortic valve replacement was associated with lower 30-day mortality (3.1% vs 7.8%) but similar 4-year survival (65.9% vs 69.6%) compared to surgical replacement in patients with severe aortic stenosis and reduced ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: